Jutila M A, Rott L, Berg E L, Butcher E C
Department of Pathology, Stanford University Medical Center, CA 94305.
J Immunol. 1989 Nov 15;143(10):3318-24.
The CD11/18 (LFA-1, Mac-1) molecules participate in neutrophil adhesion to cultured endothelium in vitro and are critical for effective neutrophil localization into inflamed tissues in vivo. More recently, the MEL-14 Ag, which was first defined as a lymphocyte homing receptor, has also been implicated in inflammatory neutrophil extravasation. Here we compare the regulation and function of these adhesion molecules on neutrophils during the in vivo inflammatory response. The MEL-14 Ag is expressed at high levels on bone marrow and peripheral blood neutrophils, but is lost on neutrophils isolated from the thioglycollate-inflamed peritoneal cavity. In contrast, Mac-1 is up-regulated on inflammatory neutrophils and little change is seen in the level of LFA-1 expression. In vitro activation of bone marrow neutrophils with PMA or leukotriene B4 results in a dose dependent increase in Mac-1 and decrease in MEL-14 Ag expression within 1 h after treatment, thus reflecting what is found during inflammation in vivo. Neutrophils activated in vitro or in vivo (MEL-14Low, Mac-1Hi) do not home to inflammatory sites in vivo, correlating with the loss of the MEL-14 Ag and the increased Mac-1 expression. Anti-LFA-1, anti-Mac-1, or MEL-14 antibody given i.v. suppress neutrophil accumulation within the inflamed peritoneum (38%, 30%, and 37% of medium control, respectively) without affecting the levels of circulating neutrophils. However, when FITC-labeled cells are precoated with the mAb and injected i.v., only MEL-14 inhibits extravasation into the inflamed peritoneum (25% of medium control). Finally, in ex vivo adhesion assays of neutrophil binding to high endothelial venules in inflamed-lymph node frozen sections MEL-14 inhibits greater than 90%. anti-LFA-1 20 to 30% and anti-Mac-1 less than 10% of the binding of bone marrow neutrophils to inflamed-lymph node high endothelial venules. These results confirm that both the MEL-14 antigen and Mac-1/LFA-1 are important in neutrophil localization to inflamed sites in vivo, but suggest that their roles in endothelial cell interactions are distinct.
CD11/18(淋巴细胞功能相关抗原-1、巨噬细胞抗原-1)分子参与体外培养条件下中性粒细胞与内皮细胞的黏附,并且对于中性粒细胞在体内有效定位于炎症组织至关重要。最近,最初被定义为淋巴细胞归巢受体的MEL-14抗原,也与炎症性中性粒细胞渗出有关。在此我们比较了体内炎症反应过程中这些黏附分子在中性粒细胞上的调节和功能。MEL-14抗原在骨髓和外周血中性粒细胞上高水平表达,但在从巯基乙酸盐诱导炎症的腹腔中分离出的中性粒细胞上消失。相反,巨噬细胞抗原-1在炎症性中性粒细胞上上调,而淋巴细胞功能相关抗原-1的表达水平变化不大。用佛波酯或白三烯B4体外激活骨髓中性粒细胞,在处理后1小时内会导致巨噬细胞抗原-1剂量依赖性增加以及MEL-14抗原表达减少,这反映了体内炎症过程中的情况。体外或体内激活的中性粒细胞(MEL-14低、巨噬细胞抗原-1高)在体内不会归巢至炎症部位,这与MEL-14抗原的丧失和巨噬细胞抗原-1表达增加相关。静脉注射抗淋巴细胞功能相关抗原-1、抗巨噬细胞抗原-1或MEL-14抗体可抑制中性粒细胞在炎症腹腔内的聚集(分别为培养基对照的38%、30%和37%),而不影响循环中性粒细胞的水平。然而,当用单克隆抗体预包被异硫氰酸荧光素标记的细胞并静脉注射时,只有MEL-14抑制其渗入炎症腹腔(为培养基对照的25%)。最后,在炎症淋巴结冰冻切片中中性粒细胞与高内皮小静脉的离体黏附试验中,MEL-14抑制超过90%。抗淋巴细胞功能相关抗原-1抑制20%至30%,抗巨噬细胞抗原-1抑制骨髓中性粒细胞与炎症淋巴结高内皮小静脉结合不到10%。这些结果证实MEL-1抗原和巨噬细胞抗原-1/淋巴细胞功能相关抗原-1在中性粒细胞在体内定位于炎症部位方面都很重要,但表明它们在内皮细胞相互作用中的作用是不同的。